newsfilter
← Earnings
Earnings Releases·

Nautilus Biotechnology — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue reached $0.2 million driven by grant and service income, while operating expenses rose 10% to $16.9 million, resulting in a net loss of $15.6 million compared to $13.6 million in the prior year period.
  • The company maintains a strong liquidity position with $114.3 million in cash, equivalents, and investments as of September 30, 2026, following $40.1 million in net cash used for operating activities over the first nine months.
  • Strategic progress includes the publication of peer-reviewed data in Nature Methods, the advancement of a 20-assay proteoform pipeline through mid-2028, and a subsequent announcement of participation in ARPA-H's SEEDS consortium for up to $6 million in funding.
  • Management reaffirmed confidence in the Voyager platform's development roadmap, targeting instrument availability in mid-2027, though the product remains subject to significant technical validation and development risks.
Company
NAUTILUS BIOTECHNOLOGY INC
Sector
Healthcare
Industry
Biotechnology